Epigenetic Drugs for Multiple Sclerosis

Author(s): Jacob Peedicayil

Journal Name: Current Neuropharmacology

Volume 14 , Issue 1 , 2016

Become EABM
Become Reviewer

Graphical Abstract:


There is increasing evidence that abnormalities in epigenetic mechanisms of gene expression contribute to the development of multiple sclerosis (MS). Advances in epigenetics have given rise to a new class of drugs, epigenetic drugs. Although many classes of epigenetic drugs are being investigated, at present most attention is being paid to two classes of epigenetic drugs: drugs that inhibit DNA methyltransferase (DNMTi) and drugs that inhibit histone deacetylase (HDACi). This paper discusses the potential use of epigenetic drugs in the treatment of MS, focusing on DNMTi and HDACi. Preclinical drug trials of DNMTi and HDACi for the treatment of MS are showing promising results. Epigenetic drugs could improve the clinical management of patients with MS.

Keywords: DNA methyltransferase inhibitor, epigenetic, histone deacetylase inhibitor, multiple sclerosis.

promotion: free to download

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2016
Page: [3 - 9]
Pages: 7
DOI: 10.2174/1570159X13666150211001600

Article Metrics

PDF: 69